Gut Zoomer: A Clinical Case Report

This case simulation—grounded in patterns observed across hundreds of clinical consultations—is designed to support evidence-informed interpretation of the Gut Zoomer Sample Report.

Clinical Narrative

A 37-year-old female presents with daily bloating and abdominal discomfort, particularly after evening meals. She also reports intermittent lower abdominal cramping and occasional loose stools alternating with normal bowel movements.

Over the past 12–18 months, she has experienced increasing anxiety and irritability. Her sleep is non-restorative, and wearable device data consistently shows poor rest, recovery, and readiness scores.

Key concerns include:

• Daily bloating and abdominal discomfort
• Intermittent lower abdominal cramping
• Loose stools alternating with normal bowel movements
• Increased anxiety and irritability
• Non-restorative sleep
• High occupational and family-related stress

She was diagnosed with diarrhea-predominant irritable bowel syndrome (IBS) three years earlier based on symptoms and recently completed rifaximin treatment for suspected small intestinal bacterial overgrowth (SIBO).

Her diet is high in convenience foods, refined carbohydrates, and red or processed meat, with limited vegetables and fermented foods. She commonly skips breakfast, drinks two to three cups of coffee daily, and consumes three to five glasses of wine per week.

Her family history includes colorectal cancer (father, dx age 58), hypothyroidism (mother), dermatitis (mother), and rheumatoid arthritis (maternal aunt).

Why Gut Zoomer Was Ordered

The provider ordered the Gut Zoomer to evaluate:

• Dysbiosis contributing to IBS-like symptoms
• Digestive insufficiency contributing to bloating and stool changes
• Intestinal permeability and mucosal immune activation
• Gut–brain axis patterns relevant to anxiety and sleep
• Modifiable gut-related factors relevant to her family history

Key Laboratory Findings

1. Dysbiosis With Reduced Keystone and Probiotic Support

Shannon’s Index was slightly below range at 2.3, while Simpson’s Index was within the normal range at 0.91. This suggests somewhat reduced microbial richness with relatively preserved evenness.

Note: A normal Simpson’s Index does not exclude the presence of pathogens. Diversity indices describe the structure of the broader microbial community, while pathogen testing evaluates specific organisms.

Several beneficial or keystone organisms were low, including:

• Akkermansia muciniphila
• Faecalibacterium prausnitzii
• Roseburia
• Roseburia intestinalis
• Eubacterium rectale
• Butyrivibrio
• Multiple Bifidobacterium and Lactobacillus species

At the same time, several organisms associated with a less favorable microbial environment were elevated:

• Escherichia coli: 22.4
• Desulfovibrio: 22.2

This combination suggests reduced microbial support for epithelial integrity and mucosal resilience alongside increased gas, sulfide, and endotoxin potential. This pattern may contribute to bloating, bowel motility variability, and intestinal barrier stress.

2. Elevated Protozoan and Fungal Findings

The pathogen section identified:

• Blastocystis hominis: 11.6 × 10³ copies/µL (reference ≤1.5e3) 
• Candida spp.: 11 × 10³ copies/µL (reference ≤1e2)
• Candida albicans: 11.2 × 10³ copies/µL (reference ≤2.5e2)

The clinical significance of a detected organism depends on its abundance and virulence, timing of exposure, microbiome composition, and host factors such as immune status, nutritional status, age, and comorbidities.

In this patient, these findings should be interpreted alongside her symptoms, recent rifaximin use, and broader dysbiosis pattern rather than viewed as isolated explanations for her presentation.

3. Intestinal Permeability and Mucosal Immune Activation

Fecal zonulin was markedly elevated at 350 ng/mL (reference 25-160), while secretory IgA was slightly below range at 425 mcg/g (reference 426-1450).

Additional findings included elevated:

• Lipopolysaccharide antibodies
• Tissue transglutaminase antibodies
• Deamidated gliadin peptide antibodies

Fecal anti-gliadin and actin antibodies remained within range.

This pattern is consistent with impaired barrier regulation and reduced mucosal immune resilience. The gluten-related antibody findings indicate immune reactivity but do not independently establish celiac disease or non-celiac gluten sensitivity. Confirmatory evaluation and clinical correlation are necessary.

4. Low-Grade Intestinal Inflammation

Calprotectin, beta-defensin 2, and MMP-9 were elevated, while fecal lactoferrin, S100A12, eosinophil protein X, and FIT remained within range.

This pattern is more consistent with low-grade mucosal immune activation than a severe acute inflammatory process.

The mildly elevated calprotectin (85.0 mcg/g) warrants follow-up, particularly if symptoms persist or worsen. Given her family history, these findings should complement (not replace) guideline-based colorectal screening and appropriate gastroenterology evaluation.

5. Digestive and Metabolic Findings

Pancreatic elastase was borderline low at 185 mcg/g (reference ≥200.0), suggesting reduced pancreatic digestive capacity.  Total fecal fat was within range, but fecal triglycerides were elevated, and both meat and vegetable fibers were detected.

These findings may reflect incomplete digestion without marked global fat malabsorption.

Short-chain fatty acid testing showed:

• Total short-chain fatty acids within range
• Butyrate within range
• Low acetate
• Propionate and valerate within range

Beta-glucuronidase was also elevated at 2,600 U/mL, which may increase intestinal deconjugation and recirculation of some hormones and environmental compounds.

The measured bile acids and LCA/DCA ratio remained within range.

6. Gut–Brain Axis Context

The urinary neurotransmitter markers remained within laboratory reference ranges. However, serotonin, GABA, and oxytocin were lower within range, while glutamate and aspartate were higher within range.

• Serotonin: 71.24 mcg/g, lower-normal
• GABA: 182.9 mcg/g, lower-normal
• Oxytocin: 267.8 mcg/g, lower-normal
• Aspartate: 2,986.7 mcg/g, upper-normal
• Glutamate: 3,460 mcg/g, upper-normal

These findings should not be interpreted as direct measures of neurotransmitter activity in the brain or as a psychiatric diagnosis.

Instead, they provide additional context when considered alongside dysbiosis, intestinal permeability, chronic stress, poor sleep, and the patient’s reported anxiety.

Key Clinical Patterns

Pattern 1: Dysbiosis Despite Preserved Microbial Evenness

The normal Simpson’s Index is clinically compatible with the detected protozoan and fungal markers. The broader pattern is defined by reduced keystone and probiotic organisms, elevated E. coli and Desulfovibrio, and symptoms consistent with gastrointestinal dysfunction.

Clinical Pearl: Low levels of keystone and commensal organisms may reduce colonization resistance, creating an environment in which opportunistic organisms such as Blastocystis and Candida can persist or expand. In this context, supporting microbial resilience with fermentable fibers, resistant starch, and polyphenol-rich foods may be more appropriate than relying solely on antimicrobial therapy. Broad antimicrobial approaches may disrupt beneficial organisms along with targeted microbes, potentially further reducing ecological balance.

Pattern 2: Barrier Dysfunction and Mucosal Immune Activation

Markedly elevated zonulin, low secretory IgA, elevated lipopolysaccharide antibodies, and mildly elevated inflammatory markers form a coherent pattern of impaired barrier function and reduced mucosal resilience.

Clinical Pearl: When barrier integrity is compromised and secretory IgA is low, the clinical priority may be to reduce ongoing mucosal stress while supporting barrier repair and immune resilience. Addressing dietary triggers, microbial imbalance, stress, sleep, and nutrient sufficiency may help create a more favorable environment for restoration of the intestinal lining.

Pattern 3: Digestive and Metabolic Dysfunction

Borderline-low pancreatic elastase, detected meat and vegetable fibers, elevated fecal triglycerides, low acetate, and elevated beta-glucuronidase suggest that impaired digestion and altered microbial metabolism may also be contributing to the clinical picture.

Clinical Pearl: Supporting parasympathetic “rest-and-digest” activity through practices that promote vagal tone may help optimize gastric, pancreatic, and biliary secretions, improve digestion and nutrient absorption, and reduce the amount of incompletely digested substrate available to opportunistic organisms.

Pattern 4: Gut–Brain Axis Stress

Dysbiosis, barrier dysfunction, low-grade inflammation, poor sleep, and high stress provide a plausible clinical framework for the coexistence of gastrointestinal symptoms and anxiety. These findings suggest association, not causation.

Clinical Pearl: Because gut–brain signaling is bidirectional, supporting both gastrointestinal function and nervous system regulation may be more effective than addressing either in isolation. Strategies that improve sleep, reduce chronic stress, support parasympathetic activity, and restore microbial balance may help reduce the physiologic inputs that reinforce both digestive symptoms and anxiety.

Clinical Applications

The Gut Zoomer revealed several overlapping patterns:

• Reduced keystone and probiotic organisms
• Elevated protozoan and fungal markers
• Increased intestinal permeability
• Reduced mucosal immune protection
• Low-grade intestinal inflammation
• Borderline digestive insufficiency
• Altered microbial metabolism
• A physiologic context relevant to gut–brain axis symptoms

These findings may help the provider prioritize further evaluation and develop a staged management plan.

Clinical considerations may include evaluating the elevated organism findings in the context of symptoms, supporting digestive and mucosal barrier function, increasing dietary diversity as tolerated, addressing sleep and stress, considering confirmatory evaluation for the elevated gluten-related antibodies, and ensuring appropriate colorectal screening.

Summary